Analgesic therapy failure in a COMT HPS/HPS diplotype carrier heterozygous for the CYP2D6 *4 allele with fibromyalgia-a case report.

ABSTRACT:

Introduction

The cytochrome P450 enzyme 2D6 (CYP2D6) and the catechol-O-methyltransferase (COMT) enzyme are involved in catecholamine metabolism, potentially influencing pain modulation. Catechol-O-methyltransferase has 3 major haplotypes related to pain sensitivity: low (LPS), average (APS), and high (HPS). However, the reliability of these haplotypes in predicting clinical outcomes is not well investigated. We present a 40-year-old female patient with fibromyalgia. Despite extensive pharmacotherapy with 120 mg/d duloxetine, 150 mg/d pregabalin, 80 mg/d oxycodone, 2 g/d paracetamol, and 1.6 g/d ibuprofen, she suffered from severe pain.

Objectives

We aim to investigate the patient's susceptibility to analgesic therapy failure (TF) and pain sensitivity with pharmacogenotyping

SUBMITTER: Bollinger A 

PROVIDER: S-EPMC11850035 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature